Clinical trial of cardiovascular protective effect of dapagliflozin on patients with HFpEF complicated with T2DM
10.13699/j.cnki.1001-6821.2025.01.003
- VernacularTitle:达格列净对HFpEF合并T2DM患者心血管保护作用的临床研究
- Author:
Zuo-ling LIU
1
;
Yun LING
1
;
Ling-yan FANG
1
Author Information
1. 广东医科大学 附属第二医院 心血管内科,广东湛江 524000
- Publication Type:Journal Article
- Keywords:
dapagliflozin tablet;
heart failure with preserved ejection fraction;
type 2 diabetes mellitus;
cardiovascular protective effect;
cardiac function;
myocardial fibrosis
- From:
The Chinese Journal of Clinical Pharmacology
2025;41(1):11-15
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the cardiovascular protective effect of dapagliflozin on patients with heart failure with preserved ejection fraction(HFpEF)complicated with type 2 diabetes mellitus(T2DM).Methods Patients with HFpEF complicated with T2DM were divided into treatment group and control group according to cohort method.The control group was given 0.5 g of metformin hydrochloride tablet orally twice a day,while the treatment group was given 10 mg of dapagliflozin tablet orally once a day on the basis of treatment in the control group.Patients in both groups were continuously treated for 6 months.The clinical efficacy after treatment and blood glucose indicators[fasting blood glucose(FBG),2 hours postprandial blood glucose(2 h PBG),glycosylated hemoglobin(HbA1 c)],echocardiographic left ventricular parameters[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular remodeling index(LVRI),left ventricular mass index(LVMI)]and serum N-terminal pro-brain natriuretic peptide(NT-proBNP),serum myocardial fibrosis indicators[matrix metalloproteinase-9(MMP-9),tissue inhibitor of metalloproteinase-1(TIMP-1)]before and after treatment were compared between both groups,and the safety evaluation was performed.Results Seventy-five cases in treatment group and 72 cases in control group were included.After treatment,the total effective rates in treatment group and control group were 93.33％(70 cases/75 cases)and 81.94％(59 cases/72 cases),respectively(P＜0.05).After treatment,the levels of FBG,2 h PBG,HbA1c,LVEF and LVEDD revealed no statistical differences between treatment group and control group(all P＞0.05).After treatment,LVRI values in treatment group and control group were(2.17±0.41)and(2.54±0.46)g·mL-2;LAMI values were(102.47±10.32)and(113.84±15.52)g·m-2;serum NT-proBNP levels were(652.38±208.26)and(993.24±302.69)pg·mL-1;MMP-9 levels were(142.52±21.67)and(168.73±25.88)mg·L-1;TIMP-1 levels were(3.68±0.84)and(3.12±0.91)μg·L-1,respectively(all P＜0.05).The total incidence rates of adverse reactions in treatment group and control group were 14.67％(11 cases/75 cases)and 12.50％(9 cases/72 cases),respectively(P＞0.05).Conclusion Dapagliflozin can improve ventricular remodeling and enhance cardiac function in patients with HFpEF complicated with T2DM,and it has a significant cardiovascular protective effect.
